Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs

NEW YORK (GenomeWeb) – Foundation Medicine said today that it is entering a strategic collaboration with Novartis focused on developing companion diagnostic tests for the company's portfolio of targeted oncology and immuno-oncology drugs.

According to Foundation, the collaboration structure includes development, regulatory support and commercialization of CDx tests using its US Food and Drug Administration-approved comprehensive genomic profiling assay, FoundationOne CDx.

Foundation said that the agreement also allows for global expansion in ex-US markets including Japan, where it has already submitted the larger FoundationOne CDx assay for regulatory approval from the Ministry of Health, Labour and Welfare in partnership with Chugai Pharmaceutical.

Melanie Nallicheri, chief business officer and head of biopharma at Foundation, said in a statement that the collaboration "reaffirms [the company's] commitment to expedite biomarker-driven development and ultimately bring more personalized treatment options to patients."

Additional terms of the deal were not disclosed and Foundation did not specify any drugs or drug candidates that it will be focusing on with Novartis.

In recent months, Foundation has also announced CDx deals with Incyte and Merck for specific therapies in those companies' pipelines.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.